My Employer Dropped GLP-1 Coverage: What to Do Next

You found out from a letter, an HR email, or a claim that bounced at the pharmacy counter: your plan no longer covers Wegovy or Zepbound the way it did. If you are already on the drug and it is working, that feels like the ground moving. If you were about to start, it feels like a door closing.

Many people are in the same position, and there is a reasonable order in which to deal with it. Work out exactly what changed, check which rules protect you, look for any coverage that is still available, and only then compare cash options. This guide walks through those steps. It is general information, not medical or legal advice. Your prescriber and your plan documents have the final word on your situation.

Why employers and state plans are dropping coverage

The short answer is cost. Brand-name GLP-1s are a large, ongoing expense for health plans, and many employers now say they cannot keep paying for them at current prices and current levels of use.

The survey data shows the trend:

• KFF's 2025 Employer Health Benefits Survey (released October 22, 2025) found that among firms offering health benefits, 16% of firms with 200 to 999 workers, 30% of firms with 1,000 to 4,999 workers, and 43% of firms with 5,000 or more workers covered GLP-1s when used mainly for weight loss.
• A Business Group on Health survey of 127 large employers, reported by SHRM on September 1, 2026, found that coverage of GLP-1s for weight management fell from 72% of respondents in 2025 to 60% in 2026. It also found that 14% have dropped the coverage or plan to drop it by 2027.

Some named examples, all verified against published sources:

• North Carolina State Health Plan. The board voted in January 2024 to end coverage of GLP-1s for weight loss, including Wegovy, Saxenda and Zepbound, effective April 1, 2024. WUNC reported that about 25,000 members with existing prescriptions were affected. Coverage for type 2 diabetes continued.
• Massachusetts Group Insurance Commission (GIC). On February 26, 2026, the commission voted 10 to 7 to drop coverage of GLP-1s prescribed solely for obesity. WBUR reported that about 22,000 members were taking a GLP-1 for weight loss. Coverage ended June 30, 2026 for non-Medicare members and runs through December 31, 2026 for Medicare members.
• Blue Cross Blue Shield of Massachusetts. The insurer said it would end GLP-1 coverage except for type 2 diabetes at each plan's renewal, starting January 1, 2026. Employers with more than 100 employees could choose to keep the coverage; smaller employers and direct-pay members could not.
• Starbucks. An Obesity Action Coalition statement dated August 21, 2026, citing Business Insider reporting, said Starbucks would end coverage of GLP-1s prescribed for weight loss beginning in October 2026, while coverage may remain for other medical conditions.

Not every change is a full exit. Some plans tighten the rules instead, and a few have added coverage back, which is why the next step matters.

Step 1: Find out exactly what changed

"My plan stopped covering Wegovy" can mean three quite different things. Your options depend on which one happened.

1. A weight-loss exclusion. The plan no longer covers GLP-1s (or all anti-obesity drugs) when prescribed for weight management. This is what North Carolina, the Massachusetts GIC and BCBS Massachusetts did. An exclusion is a change to the benefit itself, so a doctor's letter usually won't reverse it. BCBS Massachusetts states plainly that its exclusion "can't be appealed."

2. A formulary switch to a preferred drug. The plan still covers weight-loss GLP-1s, but only one brand. The best-known example came from CVS Caremark, the pharmacy benefit manager (PBM), which removed Zepbound from its standard commercial template formularies on July 1, 2025 and made Wegovy the preferred option. Its published FAQ said members who had already tried Wegovy, and either had intolerable side effects or didn't lose enough weight, could request a case-by-case formulary exception for tirzepatide. On May 28, 2026, CVS announced that Zepbound will return to those formularies as a preferred option from October 1, 2026. It also said plan sponsors can still customize coverage, so check your own plan rather than assuming. The Colorado state employee plan works the opposite way: from May 1, 2026, members on its Cigna plan have access to Zepbound for weight loss, and other drugs need a medical reason.

3. New prior-authorization, BMI or step-therapy rules. The drug is still covered, but it is harder to qualify. From January 1, 2026, the Kansas State Employee Health Plan requires a BMI of 35 or higher for weight-management GLP-1 prescriptions issued or renewed after that date. It names Wegovy as preferred, treats Zepbound as non-preferred unless an exception is approved, and requires periodic re-approval with evidence that the drug is working. Our guides to step therapy and prior authorization appeals cover this situation in detail.

How to find out which one applies to you:

• Read the notice you received, and the denial or rejection wording if a claim was refused.
• Look up your drug in your PBM's online formulary tool, or call the member services number on your pharmacy card.
• Ask HR or your benefits administrator for the Summary of Benefits and Coverage, the Summary Plan Description and any Summary of Material Modifications.
• Ask directly: "Is this an exclusion, a formulary change or a prior-authorization change? When does it take effect? Does it apply to people already on the drug? Is there an exception process?"

Step 2: Know which rules apply to your plan

Your rights depend a great deal on who funds the plan.

Fully insured plans. The employer buys a policy from an insurance company. States regulate that insurer and its contracts, so state insurance law applies, including state appeal rights and any state protections on formulary changes. Your state insurance department is the place to complain.

Self-funded plans. The employer pays claims from its own money, usually with an insurer or PBM administering them. Under ERISA, a state may not regulate a self-funded private-employer plan as if it were insurance, so most state insurance mandates don't reach it. The U.S. Department of Labor oversees these plans. This is the common arrangement: KFF reports that 67% of covered workers, and 80% of covered workers at firms with 200 or more workers, are in self-funded plans. Your insurance card may carry a big insurer's name either way, so ask HR which kind of plan you have.

State and local government plans. Governmental plans are excluded from ERISA. State employee plans like North Carolina's, Massachusetts' and Kansas's follow state law and their own governing boards. That is why their changes are often voted on at public meetings, which you can usually attend or submit comments to.

Rights that commonly apply to ERISA plans:

• Notice. When a plan adopts a material reduction in covered benefits, a summary generally must go to participants no later than 60 days after adoption. An alternative rule allows it to go out within 90 days as part of regular communications. If a change that affects the Summary of Benefits and Coverage takes effect mid-year rather than at renewal, enrollees must generally be told at least 60 days before it takes effect.
• Documents. You can request the plan documents in writing. ERISA allows courts to penalize a plan administrator who doesn't provide required information within 30 days of a request.
• Appeals and external review. Denials of claims can be appealed, and federal external review covers decisions that involve medical judgment, such as medical necessity. A plain exclusion usually isn't a medical-judgment decision. A dispute over whether the exclusion applies to you is a different matter, for example if your prescription is for a covered cardiovascular indication. Raise that with the plan in writing.

A plan can generally change its benefits at renewal. None of these rules require an employer to keep covering weight-loss drugs. What they give you is notice, documents and a fair process.

Step 3: Ask about transition fills and exceptions

There is no general federal rule that guarantees a commercial plan member a "transition fill" when a drug is dropped. But some plans and PBMs have offered bridges, so ask. Real examples:

• Grandfathering. Colorado's state employee plan previously kept coverage for existing users who refilled at least once every 120 days. That provision ended on May 1, 2026, when the plan reopened weight-loss coverage to all eligible employees.
• Carrying over an authorization when switching drugs. In the July 2025 CVS Caremark change, members with an active Zepbound prior authorization could move to Wegovy without a new PA until the original approval expired.
• Formulary exceptions. When a plan prefers one drug, there is often a medical-necessity exception route for another, as described in the Caremark and Kansas materials.
• Advance notice. BCBS Massachusetts said it planned to contact affected members no later than 60 days before their plan renewal date.

Some states limit when fully insured plans can remove drugs or change formularies during a plan year. These rules generally apply to state-regulated insurance, not self-funded plans, and they may not stop a change made at renewal. Ask your state insurance department whether any apply to you.

Step 4: Check whether another indication is still covered

This is the step people most often skip. Many plans drop coverage for weight loss but keep it for other conditions. The Massachusetts GIC, for example, continues to cover GLP-1s for diabetes, and, with prior authorization, for heart disease, sleep apnea and certain liver conditions (MASH).

The FDA-approved uses to discuss with your prescriber:

• Type 2 diabetes. Ozempic and Mounjaro are diabetes drugs. Every plan change described above kept diabetes coverage.
• Cardiovascular risk. Since March 8, 2024, Wegovy has been approved to reduce the risk of major adverse cardiovascular events, such as death, heart attack or stroke, in adults with known heart disease and either obesity or overweight.
• Obstructive sleep apnea. Since December 20, 2024, Zepbound has been approved for moderate to severe OSA in adults with obesity.
• MASH. In August 2025, Wegovy received accelerated approval for noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3).

Two cautions. First, some plans exclude everything except diabetes. BCBS Massachusetts' change covers Wegovy and Zepbound only for type 2 diabetes. Second, an indication has to genuinely fit your diagnosis and history, backed by your records. Your prescriber is the right person to judge this; it is not a paperwork workaround. If it does apply, your prescriber will usually need to submit a new prior authorization for that indication.

Step 5: If you pay cash, use the direct channels

If coverage is gone, the manufacturers' direct cash programs are usually far cheaper than paying list price at a retail pharmacy.

• Wegovy through NovoCare Pharmacy. NovoCare lists Wegovy pens at $349 a month for most doses and $399 for the 7.2 mg HD pen. New patients pay $199 a month on the two lowest doses (0.25 mg and 0.5 mg), through December 31, 2026. The Wegovy pill starts at $149 a month. See our NovoCare enrollment walkthrough and Wegovy without insurance.
• Zepbound through LillyDirect. Lilly lists vials and KwikPens at the same prices: $299 a month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 to 15 mg. The $449 tier depends on refilling within 45 days; late refills revert to regular pricing of $499 to $699. See our LillyDirect enrollment guide and Zepbound cost breakdown.
• Savings cards. Lilly's Zepbound savings program has a tier for people with commercial insurance that does not cover Zepbound, starting at $299 a month for the KwikPen, with terms that run to December 31, 2026. Our savings card guide covers the fine print.

These offers exclude people using government coverage such as Medicare, Medicaid, VA or TRICARE. Prices change often, so check the official page before you order.

Step 6: Use open enrollment deliberately

Most employer plan changes happen at renewal, so open enrollment is your best chance to act.

• Compare drug coverage, not just premiums. If your employer offers more than one plan, check each plan's formulary and any weight-management exclusion. They can differ, as Colorado's Cigna and Kaiser options did.
• Check a spouse's or partner's plan. It may cover what yours dropped. Ask for its Summary of Benefits and Coverage and formulary before enrolling.
• Do the whole-year math. Add up premiums, the deductible and expected drug costs for each option, including a year of cash pay if no plan covers the drug.
• Ask about mid-year changes. A change in drug coverage doesn't necessarily let you switch plans mid-year. Ask HR whether your plan's rules allow any election change. For how coverage works across payer types, see our GLP-1 insurance coverage guide.
• Speak up if you want to. Employer benefit decisions are revisited every year, and state plan boards take public comment.

Step 7: Use your HSA or FSA

IRS Publication 502 says prescribed medicines are a qualified medical expense. It also says weight-loss costs count when they are treatment for a disease diagnosed by a physician, such as obesity, hypertension or heart disease. In practice, this means HSA or FSA money can generally pay for a cash-pay GLP-1 prescription. Keep your prescription and receipts, and check your account administrator's rules. Paying with pre-tax money reduces the effective cost; it doesn't change the price.

If you have to stop

Sometimes none of this works and the cost is out of reach. If so, stop on purpose, with your prescriber, rather than running out of pens. A planned approach gives you more control over what comes next. Our guides cover this in detail:

• Stopping because of cost: how to do it as safely as possible
• What happens when you stop Wegovy
• What happens when you stop Zepbound
• How to taper off GLP-1 drugs

Losing coverage is not a judgment on you or your treatment. It is a benefits decision driven by price, and benefits decisions change: Colorado reopened weight-loss coverage in 2026, and CVS Caremark is putting Zepbound back on its template formularies in October. Keep your records organized and your prescriber informed, and check again at every open enrollment.

Related coverage guides

• GLP-1 letter of medical necessity (with template)
• Zepbound prior authorization
• Wegovy prior authorization
• GLP-1 coverage by PBM (CVS Caremark, Express Scripts, Optum Rx)
• Ozempic and Mounjaro prior authorization for type 2 diabetes
• How to appeal a GLP-1 prior authorization denial
• Step therapy for Wegovy and Zepbound